[ACX 2026] Will the US, UK or EU approve a gene editing therapy for a new condition during 2026?
EuropeOne-OffHealth & MedicineScience2moManifold MarketsNo KYCVerified resolution dataFairly calibratedCurrent community forecastNo 90.2%
Forecasters
29
Question type
binary
Methodology
Play-money forecasting platform
Source type
Forecast
Market data
Updated 4 hours ago
StaleJan 6, 26, 10:51 PM UTCDec 31, 26, 11:59 PM UTC
Trends
Related Markets
Related questions for context, not a comparison of equivalent contracts.
When will commercial gene-editing therapy be available?
Manifold MarketsWill a CRISPR-based gene editing therapy for transthyretin (ATTR) amyloidosis be available in the US by 2027?
Manifold MarketsBy 2030, will gene editing to cure serious genetic diseases be seen as generally uncontroversial?
Manifold MarketsWill GiveWell research gene-editing mosquitoes to eradicate malaria?
Manifold MarketsThere will be more children born via artificial wombs than not in first world countries before 2050
Manifold MarketsPreimplantation genetic diagnosis liberalised in Germany before 2027?
Manifold MarketsRules
(https://www.metaculus.com/questions/embed/41169) Resolves according to Metaculus resolution.
- Metaculus high-level description: This question will resolve as Yes if any of the US FDA, UK MHRA, or the EU Commission authorizes the use or sale of a therapy whose primary mechanism directly editing the patient's genomic DNA for any human condition other than sickle cell disease and beta thalassemia before January 1, 2027.
